These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 15383188)

  • 1. The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study.
    Didangelos TP; Thanopoulou AK; Bousboulas SH; Sambanis CL; Athyros VG; Spanou EA; Dimitriou KC; Pappas SI; Karamanos BG; Karamitsos DT
    Curr Med Res Opin; 2004 Sep; 20(9):1393-401. PubMed ID: 15383188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome.
    Tzotzas T; Samara M; Constantinidis T; Tziomalos K; Krassas G
    Angiology; 2007; 58(1):26-33. PubMed ID: 17351155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
    Halpern A; Mancini MC; Suplicy H; Zanella MT; Repetto G; Gross J; Jadzinsky M; Barranco J; Aschner P; Ramirez L; Matos AG
    Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study.
    Filippatos TD; Kiortsis DN; Liberopoulos EN; Georgoula M; Mikhailidis DP; Elisaf MS
    Curr Med Res Opin; 2005 Dec; 21(12):1997-2006. PubMed ID: 16368051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes.
    Tong PC; Lee ZS; Sea MM; Chow CC; Ko GT; Chan WB; So WY; Ma RC; Ozaki R; Woo J; Cockram CS; Chan JC
    Arch Intern Med; 2002 Nov; 162(21):2428-35. PubMed ID: 12437401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial.
    Bloch KV; Salles GF; Muxfeldt ES; Da Rocha Nogueira A
    J Hypertens; 2003 Nov; 21(11):2159-65. PubMed ID: 14597860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study.
    Lindgärde F
    J Intern Med; 2000 Sep; 248(3):245-54. PubMed ID: 10971792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.
    Derosa G; Maffioli P; Ferrari I; D'Angelo A; Fogari E; Palumbo I; Randazzo S; Cicero AF
    Fundam Clin Pharmacol; 2011 Oct; 25(5):642-51. PubMed ID: 21077943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet.
    Derosa G; Mugellini A; Ciccarelli L; Fogari R
    Clin Ther; 2003 Apr; 25(4):1107-22. PubMed ID: 12809960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of orlistat on cardiovascular disease risk in obese adults.
    Swinburn BA; Carey D; Hills AP; Hooper M; Marks S; Proietto J; Strauss BJ; Sullivan D; Welborn TA; Caterson ID
    Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with orlistat reduces cardiovascular risk in obese patients.
    Zavoral JH
    J Hypertens; 1998 Dec; 16(12 Pt 2):2013-7. PubMed ID: 9886891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E; Kolanowski J; Scheen A; Van Gaal L;
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.
    Finer N; James WP; Kopelman PG; Lean ME; Williams G
    Int J Obes Relat Metab Disord; 2000 Mar; 24(3):306-13. PubMed ID: 10757623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Maffioli P
    J Clin Pharm Ther; 2012 Apr; 37(2):187-95. PubMed ID: 21812797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin.
    Berne C;
    Diabet Med; 2005 May; 22(5):612-8. PubMed ID: 15842517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.
    Miles JM; Leiter L; Hollander P; Wadden T; Anderson JW; Doyle M; Foreyt J; Aronne L; Klein S
    Diabetes Care; 2002 Jul; 25(7):1123-8. PubMed ID: 12087008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.
    Kelley DE; Bray GA; Pi-Sunyer FX; Klein S; Hill J; Miles J; Hollander P
    Diabetes Care; 2002 Jun; 25(6):1033-41. PubMed ID: 12032111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.